|
|
.
See Category: Factors influencing health status and contact with health services
See Header: Genetic susceptibility to malignant neoplasm
ICD-10 (CM) Code and Descriptor
|
Z15.09 |
Genetic susceptibility to other malignant neoplasm
This code is considered unacceptable as a principal diagnosis.
|
Z1509 utilizaton on OPPS claims.*
Primary
ICD10 Code |
ICD10
Position 2 |
ICD10
Position 3 |
ICD10
Position 4 |
ICD10
Position 5 |
ICD10
Position 6 |
ICD10
Position 7 |
ICD10
Position 8 |
ICD10
Position 9 |
ICD10
Position 10 |
| 5.08%
|
12.07%
|
16.49%
|
15.09%
|
12.04%
|
8.73%
|
6.67%
|
5.10%
|
4.22%
|
3.03%
|
* Medicare Part A utilization data is derived from the 100% 2023 Outpatient (Fee-for-Service) Standard Analytical File.
Commonly Associated Procedure Codes for Z15.09*:
| CPT |
Description |
Number of Claims |
Sum Performed |
|
G0463
|
HOSPITAL OUTPT CLINIC VISIT |
847
|
853
|
|
36415
|
COLL VENOUS BLD VENIPUNCTURE |
408
|
409
|
|
88305
|
TISSUE EXAM BY PATHOLOGIST |
355
|
602
|
|
J2704
|
INJ, PROPOFOL, 10 MG |
347
|
11,932
|
|
80053
|
COMPREHEN METABOLIC PANEL |
284
|
284
|
|
85025
|
COMPLETE CBC W/AUTO DIFF WBC |
279
|
279
|
|
43239
|
EGD BIOPSY SINGLE/MULTIPLE |
149
|
149
|
|
88112
|
CYTOPATH CELL ENHANCE TECH |
137
|
140
|
|
82378
|
CARCINOEMBRYONIC ANTIGEN |
131
|
131
|
|
J3010
|
FENTANYL CITRATE INJECTION |
131
|
196
|
|
Q3014
|
TELEHEALTH FACILITY FEE |
130
|
131
|
|
J2250
|
INJ MIDAZOLAM HYDROCHLORIDE |
126
|
456
|
|
Q9967
|
LOCM 300-399MG/ML IODINE,1ML |
124
|
12,080
|
|
J7120
|
RINGERS LACTATE INFUSION |
118
|
146
|
|
81001
|
URINALYSIS AUTO W/SCOPE |
114
|
114
|
|
74183
|
MRI ABD W/O CNTR FLWD CNTR |
106
|
106
|
|
82565
|
ASSAY OF CREATININE |
104
|
104
|
|
G1004
|
CDSM NDSC |
97
|
119
|
|
45378
|
DIAGNOSTIC COLONOSCOPY |
92
|
92
|
|
J2405
|
ONDANSETRON HCL INJECTION |
92
|
401
|
* Derived from 100% 2021 Outpatient (Fee-for-Service) Standard Analytical File.
Z15.09 related to the following DRG Codes:
951
|
